本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

BridgeBio Pharma, Inc.

56.63
+0.13000.23%
盤後55.58-1.0500-1.85%19:52 EDT
成交量:188.10萬
成交額:1.06億
市值:108.26億
市盈率:-13.83
高:57.49
開:56.63
低:55.71
收:56.50
52周最高:57.49
52周最低:21.72
股本:1.91億
流通股本:1.51億
量比:0.76
換手率:1.24%
股息:- -
股息率:- -
每股收益(TTM):-4.0935
每股收益(LYR):-2.8793
淨資產收益率:-1789.67%
總資產收益率:-41.96%
市淨率:-6.06
市盈率(LYR):-19.67

資料載入中...

2025/01/28

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/28

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/13

重要事件披露

Form 8-K - Current report
2024/11/25

重要事件披露

Form 8-K - Current report
2024/11/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/12

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/12

重要事件披露

Form 8-K - Current report
2024/11/06

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/17

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/13

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/11

重要事件披露

Form 8-K - Current report
2024/08/21

重要事件披露

Form 8-K - Current report
2024/08/20

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/01

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/01

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/01

重要事件披露

Form 8-K - Current report
2024/07/23

重要事件披露

Form 8-K - Current report